地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18995651644
传真:18771149750
邮箱:sales@amyjet.com
<艾美捷科技代理Clearsynth品牌全系列产品
Clearsynth研发中心位于海得拉巴,以“创新与精准之心”为核心理念,打造了一个精心设计的空间,旨在激发突破性的发现并提升可能性的界限。专注于创新有机化学和独特复杂分子的合成,涵盖稳定同位素标记化合物、代谢物、杂质、葡萄糖醛酸、手性化合物、共轭物杂质和放射性标记化合物等。承接复杂分子或“难以合成”的合成化合物/中间体的定制合成服务。提供超过3,59,000个高纯度参考标准品,Clearsynth公司的产品线包括稳定同位素、原料药、杂质、亚硝胺、二级标准、散装化合物等。

▍Clearsynth服务领域
● 小分子:合成各种精细化学品和化合物,用于从毫克到数公斤规模的小分子药物发现。
● 工艺开发:开发新的合成路线,也可以修改和优化客户提供的工艺。
● 合同研发综合:专注于从临床前阶段到III期以及成功的技术转让。
● 生物核磁共振服务:位于海得拉巴的符合GLP标准的高场生物核磁共振/600MHz和300MHz设施,由敬业且经验丰富的核磁共振操作员提供支持。
● CDMO服务:致力于复杂、危险和可持续的产品和工艺。
● 分析服务:符合FDA、BIS、卫生部和其他标准机构制定的所有监管规范。
▍Clearsynth部分产品列表
| 品名 | 货号 | CAS号 |
| α-Keto Isovaleric Acid Sodium Salt 13C D6 | CS-R-00562 | 3715-29-5 (Unlabeled) |
| α-Keto Isovaleric Acid Sodium Salt 13C5 | CS-R-00482 | 1173018-24-0 |
| α-Keto Isovaleric Acid Sodium Salt D6 | CS-R-00485 | 3715-29-5(Unlabeled) |
| α-Keto Isovaleric Acid Sodium Salt Dimethyl-13C2 | CS-R-00488 | 634908-42-2 |
| α-KETOBUTYRIC ACID, SODIUM 13C, D4 | CS-R-00475 | 2013-26-5 (Unlabeled) |
| α-KETOBUTYRIC ACID, SODIUM SALT 13C4, D2 | CS-R-00477 | 360769-17-1 |
| α-KETOBUTYRIC ACID, SODIUM SALT METHYL-13C | CS-R-00478 | 634908-43-3 |
| α-KETOBUTYRIC ACID, SODIUM SALT METHYL-13C, D2 | CS-R-00479 | 1007476-77-8 |
| α-Ketobutyric Acid-d2 Sodium Salt | CS-T-30294 | 1007476-82-5 |
| α-Ketoglutaric acid 13C2, D2 | CS-CX-00331 | 123953-28-6 |
| α-KETOGLUTARIC ACID 13C5 | CS-R-00549 | 161096-83-9 |
| α-KETOGLUTARIC ACID, DISODIUM SALT 13C4 | CS-R-00480 | 1429051-79-5 |
| α-KETOISOCAPROIC ACID 13C | CS-R-00551 | 92751-19-4 |
| α-KETOISOCAPROIC ACID, SODIUM SALT 13C2 | CS-R-00552 | 4502-00-5(Unlabeled) |
| α-KETOISOCAPROIC ACID, SODIUM SALT ISOPROPYL-D7 | CS-R-00555 | 1795020-84-6 |
| α-Tocopherol-[13C3] | CS-I-00340 | 59-02-9 (Unlabeled) |
| β-ALANINE 13C | CS-R-00042 | 65138-34-3 |
| β-ALANINE 13C, 15N | CS-R-00449 | 1822942-84-6 |
| β-ALANINE 13C3 | CS-R-00040 | 107-95-9 (Unlabeled) |
| β-ALANINE 15N | CS-R-00041 | 204451-53-6 |
| β-CAROTENE 13C4 | CS-R-00567 | 7235-40-7(Unlabeled) |
| -β-Cyclocitral-d5 | CS-T-51410 | 78995-98-9 |
| β-Endosulfan D4 | CS-O-15034 | 203716-99-8 |
| β-Ionone-[13C3] | CS-I-00368 | 14901-07-6 (Unlabeled) |
| βmethasone 17-propionate-d3 | CS-O-10426 | 5534-13-4 (Unlabeled) |
| β-Tocopherol-[13C9] | CS-I-00341 | 59-02-9 (Unlabeled) |
| γ-HCH D6 | CS-EJ-0009 | 60556-82-3 |
| (-)-(2S,3S)-Viridifloric Acid Acetonide-d7 | CS-T-102816 | 95462-09-2(Unlabelled) |
| (-)-(2S,3S)-Viridifloric Acid Ethyl Ester-d7 | CS-T-102815 | 176712-53-1(Unlabelled) |
| (-)-(3S)-3-Hydroxy Quinine-vinyl-d3 | CS-T-101262 | 2734920-65-9 |
| (-)-(S)-Cibenzoline-D4 | CS-O-33254 | 103419-18-7 (Unlabeled) |
| (-)-2-Amino-6-propionamido-d3-tetrahydrobenzothiazole | CS-T-97805 | 1217644-20-6 |
| (-)-2-Methyl Isoborneol-d3 | CS-T-58298 | 135441-89-3 |
| (-)-alfa-Benidipine-d5 Hydrochloride | CS-P-07295 | 129262-07-3 (Unlabeled) |
| (-)-Cannabidiol-d9 | CS-TA-86322 | 1246819-21-5 |
| (-)-Citrinin-13C,d2 | CS-T-72877 | 1329611-85-9 |

艾美捷科技特约代理Exalpha公司产品。Exalpha位于美国迈阿密,成立20余年来,坚持以切实解决客户需求为导向,提供高品质的产品。
Exalpha was founded over 20 years ago by a group of scientists dedicated to accelerating the pace of discovery in the life science arena by rapidly developing and marketing unique products at the forefront of science.
In order to develop great products, you have to ask the right questions when you start. Where some companies are satisfied with ‘average’, ‘good enough’ or ‘me too’ products, Exalpha only settles for products that answer the pertinent questions. Exalpha continually monitors scientific trends and recent literature, we strive to produce products that answer real needs. Exalpha has a long history of developing uniquely superior products that simply perform well, allowing researchers to focus on the task at hand and not on the quality of a supplier’s products.
产品主要包括:
Buffers and Reagents
Control Antibodies
Control Lysates
Kits
Proteins and Peptides
Primary Antibodies
Secondary Antibodies
Serum
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://bangs.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Exalpha"> Exalpha
ViroStat于1985年,由Douglas McAllister博士创立,致力于为研究者和工业界提供传染性疾病的抗体产品。产品线涵盖病毒学、细菌学和寄生虫学,应用于呼吸道药、性病药、胃肠药/毒素和食源性致病菌的检测。ViroStat拥有超过500种传染性疾病相关的试剂,其中包括MONOTOPE系列单克隆抗体、PMNITOPE多克隆抗体和数量众多的重组蛋白抗原。基于长期的经验积累,ViroStat能够提供从100ug到10g级别的产品。
ViroStat was founded in 1985 by Dr. Douglas McAllister to provide infectious disease antibody tools to researchers and manufacturers. These include the areas of virology, bacteriology and parasitology. Applications for these include detection of respiratory agents, STD agents, gastrointestinal agents/toxins and food borne pathogens.
The company offers more than 500 infectious disease reagents including their MONOTOPE™ monoclonal antibodies, OMNITOPE™ polyclonal antibodies and numerous recombinant antigens. Many of these antibodies are used by manufacturers of rapid, point of care tests currently made and sold in the US.
ViroStat公司产品包括:
MONOTOPE™ - Monoclonal Antibodies (Mouse) 小鼠单克隆抗体
RABMAB® - Monoclonal Antibodies (Rabbit) 兔单克隆抗体
OMNITOPE™ - Polyclonal Antibodies多克隆抗体
RECOMBINANT ANTIGENS 重组抗原
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://bangs.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="ViroStat"> ViroStat
BioVision公司是世界顶尖的细胞凋亡和信号传导产品生产商,产品包括检测试剂盒,抗体及重组蛋白,涵盖了细胞凋亡、细胞信号传导和细胞因子研究的各个方面。凋亡产品包括Annexin V 试剂盒、半胱天冬氨酸蛋白酶(Caspases)试剂盒及底物和抑制剂、线粒体膜电位试剂盒、梯状DNA 电泳和TUNEL 试剂盒、凋亡诱导剂、凋亡相关抗体和化学品、细胞增殖检测试剂盒等。
BioVision, Inc., is a privately held Life Science company headquartered in the beautiful San Francisco Bay Area. BioVision develops and offers a wide variety of products including assay kits, antibodies, recombinant proteins & enzymes, and other innovative research tools for studying Apoptosis, Metabolism, Cell Proliferation, Cellular Stress, Cell Damage and Repair, Diabetes, Obesity and Metabolic Syndrome, Stem Cell Biology, Gene Regulation, Signal Transduction, etc. BioVision's products are currently being sold in more than 60 countries worldwide.
BioVision公司的主要产品包括:
Antibodies & Supporting Tools
Biochemicals
Cytokines & Growth Factors
ELISA Kits
Enzyme Inhibitors
EZSolution™ Ready-to-Use Products
Fluorescent Proteins
Laboratory accessories
Metabolism Assay Kits
Molecular Biology
Protein A,G,L & Affinity Conjugates
Proteins & Enzymes
Protein Extraction & Purification
Signaling Pathways
按研究领域细分
Apoptosis
Autophagy
Cardiovascular
Cancer
Cell Damage & Oxidative Stress
Cell Proliferation, Viability & Cytotoxicity
Diabetes, Obesity & Metabolic Syndrome
Drug Metabolism & Disposition
Epigenetics
Exosomes
Infectious Diseases
Metabolism
Neuroscience
Proteostasis
Signal Transduction
" data-original="http://bangs.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="BioVision"> BioVision
艾美捷科技提供Biomol品牌产品。
Biomol是一家德国综合性的生命科学产品供应商,目前有来自40个品牌的52万余种产品。
With a growing portfolio of 520,000 products from more than 40 suppliers, Biomol has been connecting researchers with products to support their discoveries for over 50 years. We combine our understanding of life science research with a curated collection of products from specialized manufacturers to meet the needs of researchers.
Biomol的主要产品包括:
Antibodies
Assays
Biological Samples
Chemicals
Cytokines
Kits
Plasmids
Primers
Proteins & Peptides
Accessory Reagents
" data-original="http://bangs.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Biomol"> Biomol
Neuromab是一家由NIH资助成立的单克隆抗体库。
The UC Davis/NIH NeuroMab Facility is a national monoclonal antibody-generating resource funded by the National Institutes of Health (NIH). The mission of the UC Davis/NIH NeuroMab Facility is to provide a unique neuroscience-based approach to generating mouse monoclonal antibodies optimized for use in mammalian brain (NeuroMabs). NeuroMabs are generated from mice immunized with synthetic and recombinant immunogens corresponding to components of the neuronal proteome as predicted from genomic and other large-scale cloning efforts. Comprehensive biochemical and immunohistochemical analyses of human, primate and non-primate mammalian brain are incorporated into the UC Davis/NIH NeuroMab Facility screening procedure. This yields a subset of mouse mAbs that are optimized for use in brain (i.e., NeuroMabs): for immunohistochemical- based imaging studies of protein localization in adult, developing and pathological brain samples, for biochemical analyses of subunit composition and post-translational modifications of native brain proteins, and for proteomic analyses of native brain protein networks.
Neuromab的主要产品包括:
Array Tomography
Model Organisms
Disease Targets
产品列表:
| 抗体名称 |
| Anti-5-formylcytidine, NeuroMab clone N358/68 |
| Anti-5-hydroxymethylcytidine, NeuroMab clone N297/59 |
| Anti-6xHis, NeuroMab clone N144/14 |
| Anti-ADAM11, NeuroMab clone N441/35 |
| Anti-ADAM22-cytoplasmic, NeuroMab clone N46/30 |
| Anti-ADAM22-extracellular, NeuroMab clone N57/2 |
| Anti-AGPS neo-epitope, NeuroMab clone N444/63 |
| Anti-Aldh1L1 (Aldehyde dehydrogenase family 1 member L1), NeuroMab clone N103/39 |
| Anti-Aldh1L1 (Aldehyde dehydrogenase family 1 member L1), NeuroMab clone N103/31 |
| Anti-Alg13, NeuroMab clone N442/28 |
| Anti-Alpha-2C adrenergic receptor, NeuroMab clone N330A/80 |
| Anti-Alpha-2C adrenergic receptor, NeuroMab clone N330A/51 |
| Anti-AMIGO-1, NeuroMab clone L86/33 |
| Anti-AMIGO-1, NeuroMab clone L86/36 |
| Anti-AMIGO-1, NeuroMab clone L86A/37 |
| Anti-Ankyrin-B, NeuroMab clone N105/13 |
| Anti-Ankyrin-B, NeuroMab clone N105/17 |
| Anti-Ankyrin-G, NeuroMab clone N106/20 |
| Anti-Ankyrin-G, NeuroMab clone N106/36 |
| Anti-Ankyrin-G, NeuroMab clone N106/65 |
| Anti-Ankyrin-G, NeuroMab clone N106/43 |
| Anti-Ankyrin-R, NeuroMab clone N388A/10 |
| Anti-Ankyrin-R/G, NeuroMab clone N388A/27 |
| Anti-ANO3/TMEM16C, NeuroMab clone N454/91 |
| Anti-ANO5/TMEM16E, NeuroMab clone N421A/85 |
| Anti-ANO6/TMEM16F, NeuroMab clone N429/19 |
| Anti-ARHGAP4, NeuroMab clone N290B/25 |
| Anti-Arl13b, NeuroMab clone N295B/66 |
| Anti-Arx, NeuroMab clone N411/51 |
| Anti-ASIC1, NeuroMab clone N271/44 |
| Anti-ATAT1, NeuroMab clone N347/42 |
| Anti-Ataxin-1 11NQ, NeuroMab clone N76/8 |
| Anti-Ataxin-1 11NQ, NeuroMab clone N76/3 |
| Anti-Ataxin-1 wild-type, NeuroMab clone N65/37 |
| Anti-ATF4, NeuroMab clone N360A/24 |
| Anti-BAF53a, NeuroMab clone N336B/83 |
| Anti-BAF53b, NeuroMab clone N332B/15 |
| Anti-Bassoon, NeuroMab clone L124/59 |
| Anti-BBS3/Arl6, NeuroMab clone N302/10 |
| Anti-BBS5, NeuroMab clone N304B/115 |
| Anti-BDNF, NeuroMab clone N450/53 |
| Anti-Beta1-spectrin, NeuroMab clone N385/21 |
| Anti-Beta4-spectrin, NeuroMab clone N393/2 |
| Anti-Beta4-spectrin, NeuroMab clone N393/76 |
| Anti-BKBeta2 potassium channel subunit, NeuroMab clone N53/32 |
| Anti-BKBeta3a potassium channel subunit, NeuroMab clone N40B/18 |
| Anti-BKBeta4 potassium channel, NeuroMab clone L18A/3 |
| Anti-Botch1/Chac1, NeuroMab clone N116/14 |
| Anti-Bral1, NeuroMab clone N364/10 |
| Anti-Bral1, NeuroMab clone N364/42 |
| Anti-Brevican, NeuroMab clone N294A/6 |
| Anti-Brevican, NeuroMab clone N294A/10 |
| Anti-CALB1/calbindin, NeuroMab clone L109/39 |
| Anti-CALB1/calbindin, NeuroMab clone L109/57 |
| Anti-CALB2/calretinin, NeuroMab clone L122/6 |
| Anti-CALB2/calretinin, NeuroMab clone L122/68 |
| Anti-CASK scaffolding protein, NeuroMab clone K56A/50 |
| Anti-Caspr/paranodin/neurexin IV, NeuroMab clone K65/35 |
| Anti-Caspr2/paranodin, NeuroMab clone K67/25 |
| Anti-Cav1.2 calcium channel, NeuroMab clone L57/46 |
| Anti-Cav1.2, NeuroMab clone N263/31 |
| Anti-Cav1.3 calcium channel, NeuroMab clone L48A/9 |
| Anti-Cav1.3 calcium channel, NeuroMab clone N38/8 |
| Anti-Cav3.1 Ca2+ channel, NeuroMab clone N178A/9 |
| Anti-Cav3.2 calcium channel, NeuroMab clone N55/10 |
| Anti-Cav1 calcium channel, NeuroMab clone N7/18 |
| Anti-Cav尾2 calcium channel subunit, NeuroMab clone N8b/1 |
| Anti-Cav3 calcium channel, NeuroMab clone N473/36 |
| Anti-Cav尾4 calcium channel, NeuroMab clone N10/7 |
| Anti-Cdkl5, NeuroMab clone EA7 |
| Anti-CDY1/2, NeuroMab clone N143/38 |
| Anti-CDY1/2/L1/L2, NeuroMab clone N143/36 |
| Anti-Celf4/Brunol4, NeuroMab clone N446/80 |
| Anti-FOS, NeuroMab clone N486/32 |
| Anti-FOS, NeuroMab clone N486/76 |
| Anti-Clcn3, NeuroMab clone N258/5 |
| Anti-Clcn4, NeuroMab clone N222/6 |
| Anti-Clcn5, NeuroMab clone N406/47 |
| Anti-CLN3, NeuroMab clone N380/87 |
| Anti-CLN6, NeuroMab clone N400/24 |
| Anti-CNGA1/3 cyclic nucleotide-gated channel, NeuroMab clone L36/12 |
| Anti-Collybistin, NeuroMab clone L120/12 |
| Anti-Collybistin, NeuroMab clone L120/30 |
| Anti-Contactin/F3 scaffold protein, NeuroMab clone K73/20 |
| Anti-Copper-transporting ATPase 1, NeuroMab clone L60/4 |
| Anti-Copper-transporting ATPase 2 (Copper pump 2, Wilsons disease-associated protein, NeuroMab clone L62/29 |
| Anti-Co-Rest/RCOR1 Transcriptional Co-Repressor, NeuroMab clone K72/8 |
| Anti-DEPDC5, NeuroMab clone N463/52 |
| Anti-Dicer, NeuroMab clone N167/7 |
| Anti-DLX1 transcription factor, NeuroMab clone L43/40 |
| Anti-DNAH1, NeuroMab clone N251/14 |
| Anti-DNAH7, NeuroMab clone N250/21 |
| Anti-DNAIC1, NeuroMab clone UNC 65.56.18.11 |
| Anti-DNMT3L, NeuroMab clone N117/9 |
| Anti-Doc2b, NeuroMab clone N150/21 |
| Anti-Dopamine D2 receptor, NeuroMab clone N186/29 |
| Anti-Dopamine D3 receptor, NeuroMab clone N331/19 |
| Anti-EAAC1, NeuroMab clone N420/24 |
| Anti-FGF11 (Fibroblast growth factor 11), NeuroMab clone N92/14 |
| Anti-FGF12/FHF1, NeuroMab clone N94/17 |
| Anti-FGF13 (Fibroblast growth factor 13), NeuroMab clone N91/27 |
| Anti-FGF13B/FHF2B, NeuroMab clone N225A/10 |
| Anti-FGF14/FHF4, NeuroMab clone N56/21 |
| Anti-Fig4/Sac3, NeuroMab clone N202/7 |
| Anti-Flrt3, NeuroMab clone N353/13 |
| Anti-Foxi2, NeuroMab clone N349/96 |
| Anti-Foxi3, NeuroMab clone N359/28 |
| Anti-Frataxin, NeuroMab clone N191/7 |
| Anti-GABA-A-R-Alpha1, NeuroMab clone N95/35 |
| Anti-GABA-A-R-Alpha2, NeuroMab clone N399/19 |
| Anti-GABA-A-R-Alpha4, NeuroMab clone N398A/34 |
| Anti-GABA-A-R-Alpha5, NeuroMab clone N415/24 |
| Anti-GABA-A-R-Alpha6, NeuroMab clone N229A/32 |
| Anti-GABA-A-R-Beta1, NeuroMab clone N96/55 |
| Anti-GABA-A-R-Beta2/3, NeuroMab clone 62-3G1 |
| Anti-GABA-A-R-Beta3, NeuroMab clone N87/25 |
| Anti-Delta GABA-A receptor, NeuroMab clone N151/3 |
| Anti-GABA-A-R-Epsilon, NeuroMab clone N413/67 |
| Anti-GABA-A-R-Gamma2L, NeuroMab clone N452/69 |
| Anti-GABA-A-R-Gamma2L/S, NeuroMab clone N452/73 |
| Anti-GABA-A-R-Gamma2L/S, NeuroMab clone N452/30 |
| Anti-GABA-A-R-Pi, NeuroMab clone N431/64 |
| Anti- GABA-A-R-Theta, NeuroMab clone L123/109 |
| Anti-GABABR1 GABA-B receptor, NeuroMab clone N93A/49 |
| Anti-GABABR2 GABA-B receptor, NeuroMab clone N81/2 |
| Anti-GABABR2 GABA-B receptor, NeuroMab clone N81/37 |
| Anti-GAD65/67, NeuroMab clone L127/12 |
| Anti-GAD67, NeuroMab clone L127/8 |
| Anti-Gamma-protocadherin-A3, NeuroMab clone N144/17 |
| Anti-Gamma-protocadherin-B2, NeuroMab clone N148/30 |
| Anti-Gamma-protocadherin-C3, NeuroMab clone N174B/27 |
| Anti-Gamma-protocadherin-C4, NeuroMab clone N193A/13 |
| Anti-Gephyrin, NeuroMab clone L106/83 |
| Anti-Gephyrin, NeuroMab clone L106/93 |
| Anti-Gephyrin, NeuroMab clone L106/4 |
| Anti-GFAP, NeuroMab clone N206A/8 |
| Anti-GFAP-R416WT, NeuroMab clone N206B/9 |
| Anti-GFP (Green fluorescent protein), NeuroMab clone N86/8 |
| Anti-GFP (Green fluorescent protein), NeuroMab clone N86/38 |
| Anti-GFP (green fluorescent protein), NeuroMab clone N86/20 |
| Anti-GFP (green fluorescent protein), NeuroMab clone N86/44 |
| Anti-GIT1 scaffold protein, NeuroMab clone N39B/8 |
| Anti-GIT2 scaffold protein, NeuroMab clone N83/48 |
| Anti-GluA1/GluR1 glutamate receptor, NeuroMab clone N355/1 |
| Anti-GluA2/GluR2 glutamate receptor, NeuroMab clone L21/32 |
| Anti-KA2 kainate receptor, NeuroMab clone N279B/27 |
| Anti-GluN1/NR1 glutamate receptor, NeuroMab clone N308/48 |
| Anti-NR2A glutamate receptor, NeuroMab clone N327A/38 |
| Anti-GluN2A/NR2A glutamate receptor, NeuroMab clone N327/95 |
| Anti-GluN2B/NR2B glutamate receptor, NeuroMab clone N59/20 |
| Anti-GluN2B/NR2B glutamate receptor, NeuroMab clone N59/36 |
| Anti-GluN2C/NR2C, NeuroMab clone N422/18 |
| Anti- GluN3A/NR3A, NeuroMab clone N416/40 |
| Anti-Glycine receptor Alpha3, NeuroMab clone N424/45 |
| Anti-Glycine receptor Alpha3L, NeuroMab clone N424/48 |
| Anti-GRK6A/B, NeuroMab clone N142/28 |
| Anti-Gs protein alpha subunit, NeuroMab clone N192/12 |
| Anti-GST (Glutathione S-transferase), NeuroMab clone N100/13 |
| Anti-Haspin/GSG2, NeuroMab clone N128A/2 |
| Anti-HCN1 cyclic nucleotide-gated channel, NeuroMab clone N70/28 |
| Anti-HCN2 cyclic nucleotide-gated channel, NeuroMab clone N71/37 |
| Anti-HCN3 cyclic nucleotide-gated channel, NeuroMab clone N141/28 |
| Anti-HCN4 cyclic nucleotide-gated channel, NeuroMab clone N114/10 |
| Anti-Histone H2A.Z/V, NeuroMab clone N310/21 |
| Anti-Histone H2A.Z acetyl-Lys4/7/11, NeuroMab clone N299/39 |
| Anti-Histone H3.3, NeuroMab clone N158/28 |
| Anti-Histone H3 acetyl-Lys56, NeuroMab clone N307/12 |
| Anti-Histone H3-dimethyl-Arg8, NeuroMab clone N293/50 |
| Anti-Histone H3 pThr11, NeuroMab clone N123/19 |
| Anti-Histone H3 pThr11, NeuroMab clone N123/48 |
| Anti-Histone H4-dimethyl-Arg3, NeuroMab clone N309A/21 |
| Anti-Homer1L, NeuroMab clone L113/27 |
| Anti-Homer1L, NeuroMab clone L113/13 |
| Anti-Homer1, NeuroMab clone L113/130 |
| Anti-ICK, NeuroMab clone N451/73 |
| Anti-Iduna/RNF146, NeuroMab clone N201/35 |
| Anti-INPP4b, NeuroMab clone N171/17 |
| Anti IP3 receptor type 1 NeuroMab clone L24/18 |
| Anti-IRSp53/BAIAP2, NeuroMab clone L117/1 |
| Anti-JIP-2/IB-2, NeuroMab clone N135/37 |
| Anti-JMJD2A, NeuroMab clone N154/32 |
| Anti-KCC2 transporter, NeuroMab clone N1/66 |
| Anti-KCC2 transporter, NeuroMab clone N1/12 |
| Anti-KChIP1 potassium channel, NeuroMab clone K55/7 |
| Anti-KChIP2 potassium channel subunit, NeuroMab clone K60/73 |
| Anti-KChIP3 potassium channel, NeuroMab clone K66/38 |
| Anti-KChIP4 K+ channel, NeuroMab clone N423/75 |
| Anti-KCNT1/Slo2.2/Slack K+ channel, NeuroMab clone N3/26 |
| Anti-KCNT2/Slo2.1/Slick sodium- and chloride-activated ATP sensitive potassium channel, NeuroMab clone N11/33 |
| Anti-KCNU1/Slo3 pH-sensitive maxi potassium channel, NeuroMab clone N2/16 |
| Anti-Keyhole limpet hemocyanin, NeuroMab clone N132A/12 |
| Anti-Kir2.1 potassium channel, NeuroMab clone N112B/14 |
| Anti-Kir2.2 potassium channel, NeuroMab clone N124B/38 |
| Anti-Kir2.3 potassium channel, NeuroMab clone N25/35 |
| Anti-Kir2.4 potassium channel, NeuroMab clone N465/11 |
| Anti-Kir3.3 potassium channel, NeuroMab clone N455/15 |
| Anti-Kir6.1 potassium channel, NeuroMab clone N366/60 |
| Anti-Kir6.2 potassium channel, NeuroMab clone N363/71 |
| Anti-Kirrel3 short and long, NeuroMab clone N321C/49 |
| Anti-Kirrel3 short isoform 3, NeuroMab clone N320/48 |
| Anti-Kv1.1 potassium channel subunit, NeuroMab clone K20/78 |
| Anti-Kv1.1 potassium channel (external), NeuroMab clone K36/15 |
| Anti-Kv1.2 potassium channel subunit, NeuroMab clone K14/16 |
| Anti-Kv1.2 potassium channel subunit, NeuroMab clone L76/36 |
| Anti-Kv1.3 potassium channel, NeuroMab clone L23/27 |
| Anti-Kv1.4 potassium channel subunit, NeuroMab clone K13/31 |
| Anti-Kv1.4 potassium channel (extracellular), NeuroMab clone L71/5 |
| Anti-Kv1.5 potassium channel, NeuroMab clone K7/45 |
| Anti-Kv1.6 potassium channel subunit, NeuroMab clone K19/36 |
| Anti-Kv1.7 potassium channel, NeuroMab clone N471/27 |
| Anti-Kv11.3 potassium channel, NeuroMab clone N447/24 |
| Anti-Kv2.1 potassium channel subunit, NeuroMab clone L83/11 |
| Anti-Kv2.1 potassium channel subunit, NeuroMab clone K89/34 |
| Anti-Kv2.1 potassium channel subunit, NeuroMab clone L80/21 |
| Anti-Kv2.1 potassium channel (external), NeuroMab clone K39/25 |
| Anti-Kv2.2 potassium channel, NeuroMab clone K37/89 |
| Anti-Kv2.2 potassium channel, NeuroMab clone N372C/51 |
| Anti-Kv2.2 potassium channel, NeuroMab clone N372B/60 |
| Anti-Kv2.2 potassium channel, NeuroMab clone N372B/1 |
| Anti-Kv3.1b potassium channel, NeuroMab clone N16b/8 |
| Anti-Kv3.2 potassium channel, NeuroMab clone N410/17 |
| Anti-Kv3.3 potassium channel, NeuroMab clone N375/67 |
| Anti-Kv3.4 potassium channel, NeuroMab clone N72/16 |
| Anti-Kv4.2 potassium channel subunit, NeuroMab clone L28/4 |
| Anti-Kv4.2 potassium channel (external), NeuroMab clone K57/1 |
| Anti-Kv4.3 potassium channel subunit, NeuroMab clone K75/41 |
| Anti-Kv4.3 potassium channel subunit, NeuroMab clone K75/30 |
| Anti-Kv6.1 potassium channel, NeuroMab clone N474/27 |
| Anti-Kv6.4 potassium channel, NeuroMab clone N458/10 |
| Anti-KCNQ1 potassium channel, NeuroMab clone N37A/10 |
| Anti-KCNQ2 potassium channel, NeuroMab clone N26A/23 |
| Anti-KCNQ4 potassium channel, NeuroMab clone N43/6 |
| Anti-Kv8.2 potassium channel, NeuroMab clone N448/88 |
| Anti-Kv8.2 potassium channel, NeuroMab clone N448/50 |
| Anti-Kv9.1 potassium channel, NeuroMab clone N461/19 |
| Anti-Kv9.2 potassium channel, NeuroMab clone N460/19 |
| Anti-Kvβ1.1 potassium channel subunit, NeuroMab clone K9/40 |
| Anti-Kv1.2 potassium channel subunit, NeuroMab clone K47/42 |
| Anti-Kv尾2 potassium channel, NeuroMab clone K17/70 |
| Anti-Laforin, NeuroMab clone N84/37 |
| Anti-LAR/PTPRF, NeuroMab clone N165/38 |
| Anti-Lgi1, NeuroMab clone N283/7 |
| Anti-Lhx6.1, NeuroMab clone N228A/16 |
| Anti-LRP4 (cytoplasmic), NeuroMab clone N164/6 |
| Anti-LRP4 (extracellular), NeuroMab clone N207/27 |
| Anti-LRRK1, NeuroMab clone N341/37 |
| Anti-LRRK1, NeuroMab clone N341/12 |
| Anti-LRRK2/Dardarin, NeuroMab clone N241A/34 |
| Anti-LRRK2/Dardarin, NeuroMab clone N231B/34 |
| Anti-LRRK2/Dardarin, NeuroMab clone 8G10 |
| Anti-LRRK2/Dardarin, NeuroMab clone N138/6 |
| Anti-LRRK2/Dardarin-pSer910, NeuroMab clone 1D8 |
| Anti-LRRTM2, NeuroMab clone N209C/35 |
| Anti-LRRTM4, NeuroMab clone N205B/22 |
| Anti-Mad3, NeuroMab clone N129A/6 |
| Anti-Mad3, NeuroMab clone N129/15 |
| Anti-Malin, NeuroMab clone N85/18 |
| Anti-MBP (Maltose-binding protein), NeuroMab clone N128A/4 |
| Anti-MAP3K12, NeuroMab clone N377/20 |
| Anti-MAP3K12, NeuroMab clone N377/83 |
| Anti-MECP2, NeuroMab clone N227/21 |
| Anti-MESD, NeuroMab clone N88/12 |
| Anti-MFF, NeuroMab clone N382/14 |
| Anti-MFF (exon 1), NeuroMab clone N382/69 |
| Anti-MGL, NeuroMab clone N90/20 |
| Anti-mGluR1/5 (group I) glutamate receptor, NeuroMab clone N75/3 |
| Anti- mGluR1/5 (group I) glutamate receptor, NeuroMab clone N75/33 |
| Anti-Miro2, NeuroMab clone N384/63 |
| Anti-MiRP4 potassium channel, NeuroMab clone N472/88 |
| Anti-Mitofusin-1 (Mfn1), NeuroMab clone N111/24 |
| Anti-Mitofusin-2 (Mfn2), NeuroMab clone N153/5 |
| Anti-MMACHC, NeuroMab clone N230/21 |
| Anti-MMP9 metalloproteinase, NeuroMab clone L51/82 |
| Anti-MOG, NeuroMab clone L94/54 |
| Anti-Mortalin/GRP75, NeuroMab clone N52A/42 |
| Anti-MPP8, NeuroMab clone N119/44 |
| Anti-NALCN, NeuroMab clone N185/7 |
| Anti-Nav1.1 sodium channel, NeuroMab clone K74/71 |
| Anti-Nav1.2 sodium channel, NeuroMab clone K69/3 |
| Anti-Nav1.4 sodium channel, NeuroMab clone N255/38 |
| Anti-Nav1.5 sodium channel, NeuroMab clone N397/19 |
| Anti-Nav1.6 sodium channel, NeuroMab clone K87A/10 |
| Anti-Nav1.7 sodium channel, NeuroMab clone N68/6 |
| Anti-Nav1.8 sodium channel, NeuroMab clone N134/12 |
| Anti-Navbeta1 Na+ channel, NeuroMab clone N405/74 |
| Anti-Navbeta2 Na+ channel, NeuroMab clone N395/68 |
| Anti-Navbeta3 Na+ channel, NeuroMab clone N396/29 |
| Anti-Navbeta4 sodium channel, NeuroMab clone N168/6 |
| Anti-NCKX4, NeuroMab clone N414/25 |
| Anti-Neuregulin-CRD (Cysteine-rich domain, Type III), NeuroMab clone N126B/31 |
| Anti-Neuregulin-HBD (Heparin-binding domain, Type I/II), NeuroMab clone N120A/9 |
| Anti-Neurexin-1-Beta, NeuroMab clone N170A/1 |
| Anti-Neurexin-1-Beta, NeuroMab clone N170A/26 |
| Anti-Neuroligin-1, NeuroMab clone N97A/31 |
| Anti-Neuroligin-2, NeuroMab clone L107/39 |
| Anti-Neuroligin-3, NeuroMab clone N110/29 |
| Anti-Neuroligin-4*, NeuroMab clone N98/47 |
| Anti-Neuroligin-4*, NeuroMab clone N98/7 |
| Anti-NGL-1 (Netrin-G1 ligand), NeuroMab clone N49A/21 |
| Anti-NGL-2 (Netrin-G2 ligand) NeuroMab clone N50/36 |
| Anti-NGL-3 (Netrin-G3 ligand), NeuroMab clone N51/6 |
| Anti-NKCC1, NeuroMab clone N161/20 |
| Anti-NOS1/nNOS, NeuroMab clone L121/25 |
| Anti-NOS1/nNOS, NeuroMab clone L121/42 |
| Anti-Notch1, NeuroMab clone N253/32 |
| Anti-Npas4, NeuroMab clone N408/62 |
| Anti-Npas4, NeuroMab clone N408/79 |
| Anti-Neuropeptide Y, NeuroMab clone L115/13 |
| Anti-NPY2R, NeuroMab clone L119/106 |
| Anti-NrCAM, NeuroMab clone N343/26 |
| Anti-NSD1, NeuroMab clone N312/10 |
| Anti-NSD3, NeuroMab clone N348/82 |
| Anti-OCRL/INPP5b, NeuroMab clone N166A/26 |
| Anti-Olig1, NeuroMab clone N149/25 |
| Anti-Pan-Ankyrin, NeuroMab clone N388A/60 |
| Anti-Pancortin, NeuroMab clone K96/7 |
| Anti-Pan-FHF-A, NeuroMab clone N235/22 |
| Anti-Pan-Gamma-protocadherin-A, NeuroMab clone N144/32 |
| Anti-Pan-Gamma-protocadherin, NeuroMab clone N159/5 |
| Anti-Pan-GRK, NeuroMab clone N145/20 |
| Anti-Pan-KChIP potassium channel, NeuroMab clone K55/82 |
| Anti-Pan-Kv potassium channel, NeuroMab clone K40/17 |
| Anti-Pan-Kvbeta potassium channel, NeuroMab clone K25/73 |
| Anti-Pan-MAGUK scaffold proteins, NeuroMab clone K28/86 |
| Anti-Pan-Nav1 sodium channel, NeuroMab clone N419/40 |
| Anti-Pan-Nav1 sodium channel, NeuroMab clone N419/78 |
| Anti-pan-Neurofascin, NeuroMab clone L11A/41 |
| Anti-Pan-Neurofascin (external), NeuroMab clone A12/18 |
| Anti-Pannexin-2, NeuroMab clone N121A/1 |
| Anti-Pannexin-2, NeuroMab clone N121A/31 |
| Anti-Pan-PTPR, NeuroMab clone N165/43 |
| Anti-Pan-QKI, NeuroMab clone N147/6 |
| Anti-Pan-SAPAP, NeuroMab clone N127/31 |
| Anti-pan-Shank (SH3 and multiple ankyrin repeat domains protein) scaffold protein, NeuroMab clone N23B/49 |
| Anti-Pan-Synapsin, NeuroMab clone L125/129 |
| Anti-Pan-Thyroid hormone receptor, NeuroMab clone N403/63 |
| Anti-PARIS/ZNF746, NeuroMab clone N196/16 |
| Anti-Parvalbumin, NeuroMab clone L114/3 |
| Anti-Parvalbumin, NeuroMab clone L114/81 |
| Anti-PEX6, NeuroMab clone N233/8 |
| Anti-PEX7, NeuroMab clone N232/9 |
| Anti-Phosphoserine-2-OEt, NeuroMab clone N257/25 |
| Anti-Phosphoserine-2-OH, NeuroMab clone N259/48 |
| Anti-Phosphoserine-2-OMe, NeuroMab clone N262/16 |
| Anti-PhyH/PAHX, NeuroMab clone N210/5 |
| Anti-PICK1 scaffold, NeuroMab clone L20/8 |
| Anti-PINK1, NeuroMab clone N4/15 |
| Anti-PINK1, NeuroMab clone N4/49 |
| Anti-PINK1, NeuroMab clone N4/19 |
| Anti-PINK1, NeuroMab clone N357/6 |
| Anti-Proser1, NeuroMab clone N456/39 |
| Anti-Prrt2, NeuroMab clone N485/22 |
| Anti-PSD-93/Chapsyn-110 scaffold protein, NeuroMab clone N18/30 |
| Anti-PSD-93/Chapsyn-110 scaffold protein, NeuroMab clone N18/28 |
| Anti-PSD-95 MAGUK scaffold protein, NeuroMab clone K28/43 |
| Anti-PSD-95 MAGUK scaffold protein, NeuroMab clone K28/74 |
| Anti-QKI-5-NLS, NeuroMab clone N195A/16 |
| Anti-QKI-6, NeuroMab clone N182/17 |
| Anti-QKI-7, NeuroMab clone N183/15 |
| Anti-QKI-7b, NeuroMab clone N194/11 |
| Anti-RBM17/SPF45, NeuroMab clone N219/5 |
| Anti-REEP, NeuroMab clone N326D/13 |
| Anti-REEP1, NeuroMab clone N345/51 |
| Anti-REEP1/2, NeuroMab clone N326D/29 |
| Anti-REEP2, NeuroMab clone N326D/2 |
| Anti-Rem2, NeuroMab clone N324/2 |
| Anti-RGS14, NeuroMab clone N133/21 |
| Anti-RGS14, NeuroMab clone N133/35 |
| Anti-Rufy3, NeuroMab clone N483/84 |
| Anti-Rufy3, NeuroMab clone N483/126 |
| Anti-Rufy3, NeuroMab clone N483/26 |
| Anti-S100A5, NeuroMab clone N176A/35 |
| Anti-SALM2 synaptic adhesion-like molecule, NeuroMab clone N52B/27 |
| Anti-SALM5/LRFN5, NeuroMab clone N140A/12 |
| Anti-SAP102 MAGUK scaffold protein, NeuroMab clone N19/2 |
| Anti-SAP97 scaffold protein, NeuroMab clone K64/15 |
| Anti-SAPAP1, NeuroMab clone N238/29 |
| Anti-SAPAP1, NeuroMab clone N238/30 |
| Anti-SAPAP1/2, NeuroMab clone N238/31 |
| Anti-SAPAP2, NeuroMab clone N459/84 |
| Anti-SAPAP3, NeuroMab clone L126/93 |
| Anti-SCG10/stathmin-2, NeuroMab clone L5/1 |
| Anti-SH3GL1, NeuroMab clone K51/1 |
| Anti-Shank1/ SPANK-1/Synamon/SSTRIP scaffold protein, NeuroMab clone N22/21 |
| Anti-Shank1 and Shank3, NeuroMab clone N367/51 |
| Anti-Shank2/ProSAP1/Spank-3/CortBP1 scaffold protein,NeuroMab clone N23B/6 |
| Anti-Shank3 scaffold protein, NeuroMab clone N69/46 |
| Anti-Shank3, NeuroMab clone N367/62 |
| Anti-SK2 potassium channel, NeuroMab clone K78/29 |
| Anti-Slo1/BKAlpha potassium channel, NeuroMab clone L6/23 |
| Anti-Slo1/BKAlpha potassium channel, NeuroMab clone L6/48 |
| Anti-Slo1/BKAlpha potassium channel, NeuroMab clone L6/60 |
| Anti-Snapin (SNAP25 binding protein), NeuroMab clone L8/15 |
| Anti-SNAT1 Neurotransmitter Transporter NeuroMab clone N104/37 |
| Anti-SNAT1 Neurotransmitter Transporter NeuroMab clone N104/32 |
| Anti-SST/Somatostatin, NeuroMab clone L111/118 |
| Anti-S-tag, NeuroMab clone N56/9 |
| Anti-Stonin-2, NeuroMab clone N346/9 |
| Anti-SUR1, NeuroMab clone N289/16 |
| Anti-SUR1 and SUR2B, NeuroMab clone N323A/31 |
| Anti-SUR2A, NeuroMab clone N319A/14 |
| Anti-SUR2B, NeuroMab clone N323B/20 |
| Anti-SVOP, NeuroMab clone N356/9 |
| Anti-SVOP, NeuroMab clone N356/23 |
| Anti-Synapsin-III, NeuroMab clone L125/121 |
| Anti-Synaptotagmin-10, NeuroMab clone N269/73 |
| Anti-Synaptotagmin-12, NeuroMab clone N277/7 |
| Anti-Synaptotagmin-3, NeuroMab clone N278/19 |
| Anti-Synaptotagmin-5, NeuroMab clone N274/8 |
| Anti-Synaptotagmin-6, NeuroMab clone N270/47 |
| Anti-Synaptotagmin-7, NeuroMab clone N275/14 |
| Anti-Synaptotagmin-9, NeuroMab clone N276A/15 |
| Anti-SynCAM1 cell adhesion molecule, NeuroMab clone L45/30 |
| Anti-SynCAM4, NeuroMab clone N244/5 |
| Anti-SynDIG1/Tmem90b, NeuroMab clone L42/17 |
| Anti-SynDIG3/Tmem91, NeuroMab clone N160/21 |
| Anti-SynDIG4, NeuroMab clone L102/45 |
| Anti-Tafazzin, NeuroMab clone N173B/13 |
| Anti-TALK1 potassium channel, NeuroMab clone N466/14 |
| Anti-TARPGamma2/Stargazin, NeuroMab clone N245/1 |
| Anti-TARPGamma2/4/8, NeuroMab clone N245/36 |
| Anti-TASK1 potassium channel, NeuroMab clone N374/48 |
| Anti-Tauro-GM2, NeuroMab clone N175/9 |
| Anti-THAP1, NeuroMab clone N325B/65 |
| Anti-THIK-2 potassium channel, NeuroMab clone N468/37 |
| Anti-Thioredoxin, NeuroMab clone N245/44 |
| Anti-Thorase (Atad1), NeuroMab clone N125/10 |
| Anti-Thyroid hormone receptor beta1, NeuroMab clone N402/13 |
| Anti-Thyroid hormone receptor beta1, NeuroMab clone N402/46 |
| Anti- TRAAK potassium channel, NeuroMab clone N445/27 |
| Anti-TRAK1, NeuroMab clone N389/9 |
| Anti-TRAK2, NeuroMab clone N390/43 |
| Anti-TRESK potassium channel, NeuroMab clone N467/1 |
| Anti-TRIP8b (constant), NeuroMab clone N212/7 |
| Anti-TRIP8b (constant), NeuroMab clone N212/17 |
| Anti-TRIP8b (exon 1a/5 junction), NeuroMab clone N291C/22 |
| Anti-TRIP8b (exon 1b), NeuroMab clone N212A/34 |
| Anti-TRIP8b (exon 4), NeuroMab clone N212/3 |
| Anti-TrpC1 calcium channel, NeuroMab clone 1F1 |
| Anti-TrpC4 calcium channel, NeuroMab clone N77/15 |
| Anti-TrpC5 calcium channel, NeuroMab clone N67/15 |
| Anti-TrpC7 calcium channel, NeuroMab clone N64A/36 |
| Anti-TrpM4, NeuroMab clone L88/86 |
| Anti-TrpM6, NeuroMab clone N470/22 |
| Anti-TrpM7 ion channel and Ser/Thr kinase, NeuroMab clone N74/25 |
| Anti-TRPML3/Mucolipin-3, NeuroMab clone N268/19 |
| Anti-TrpV1, NeuroMab clone N221/17 |
| Anti-TrpV1, NeuroMab clone N221/12 |
| Anti-TrpV3 cation channel, NeuroMab clone N15/4 |
| Anti-TrpV3 cation channel, NeuroMab clone N15/39 |
| Anti-TWIK-2 potassium channel, NeuroMab clone N469/28 |
| Anti-Uncx, NeuroMab clone N155/9 |
| Anti-VAChT vesicular acetylcholine transporter, NeuroMab clone N6/38 |
| Anti-VAChT, NeuroMab clone N425/45 |
| Anti-VAPA, NeuroMab clone N479/12 |
| Anti-VAPA, NeuroMab clone N479/22 |
| Anti-VAPA/B, NeuroMab clone N479/107 |
| Anti-VDAC1, NeuroMab clone N152B/23 |
| Anti-Versican, NeuroMab clone N351/23 |
| Anti-Versican, NeuroMab clone N351/24 |
| Anti-VGAT, NeuroMab clone L118/80 |
| Anti-VGAT, NeuroMab clone L118/66 |
| Anti-VGlut1, NeuroMab clone N28/9 |
| Anti-VGlut2, NeuroMab clone N29/29 |
| Anti-VGlut3, NeuroMab clone N34/34 |
| Anti-VIP, NeuroMab clone L108/92 |
| Anti-VMAT1, NeuroMab clone N440/21 |
| Anti-VMAT1, NeuroMab clone N440/61 |
| Anti-Slc18a2/VMAT2, NeuroMab clone N449/73 |
| Anti-Zebrafish VSP/TPTE, NeuroMab clone N432/21 |
| Anti-Zebrafish VSP/TPTE, NeuroMab clone N432/63 |
| Anti-WAVE1/SCAR, NeuroMab clone K91/36 |
| Anti-WNK1, NeuroMab clone N391/68 |
| Anti-WRN, NeuroMab clone N428/12 |
| Zebrafish PSD Marker, NeuroMab clone N286/74 |
| Anti-Zinedin/Striatin-4, NeuroMab clone K88/64 |
| Anti-ZIP3, NeuroMab clone N476/9 |
| Anti-ZNF423, NeuroMab clone N328B/37 |

Laysanbio专业提供聚乙二醇类产品,包括多臂聚乙二醇,亲核聚乙二醇,羧基聚乙二醇,亲电型聚乙二醇类,亲电型琥珀酰亚胺基聚乙二醇类,巯基聚乙二醇类。
Laysan Bio, Inc. (Laysan) is a Biotechnology company that offers novel polymers to customers for development of a wide variety of platforms. The management team and key employees have been involved with the development and supply of PEG reagents for seven FDA or EU approved drug products or medical devices including Neulasta®, Somavert®, PEGASYS®, PEG-INTRON®, Definity®, Macugen® and DuraSeal™.
主要产品包括:
Acrylates (ACRL)
Aldehydes (bALD, pALD)
Amines (NH2)
Biotins (BIO)
Carboxylic Acids (COOH, ASA)
Epoxides (EPOX)
Esters (NHS, SAS, SC, SCM, SG, SS, SVA)
Hydrazides (HZ)
Hydroxyls (OH)
Kits of PEG reagents
Maleimides (MAL)
Multi-Arms (4 arm)
Nitrophenyl Carbonates (NPC)
Orthopyridyl Disulfide (OPSS)
Phospholipids (DSPE)
Protected Amines (FMOC, tBOC)
Silane (SIL)
Thiols (SH)
Valeric Acids (VA)
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://bangs.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Laysan Bio"> Laysan Bio
作为全球血栓与止血诊断领域的领导者,Stago公司的使命是为实验室人员及临床医生提供可靠准确的血栓与止血疾病诊断工具,从而更有效地认知、治疗和监测相关疾病,改善患者生活。
From Research & Development and Production to Logistics, Marketing, Sales and International Distribution, Stago remains in control of its strategy at all levels. Certified ISO 13485, ISO 9001 (2008) and ISO 14001 for its main reagent manufacturing plant. the group’s industrial activities are mostly concentrated in France. Its geographical expansion has led to opening R&D and production centers in the USA, Netherlands, Germany, Ireland and China.
Ever since our American subsidiary was established in 1985, our distribution network grew considerably throughout the world. Since 2003, 17 new affiliates have been opened: China (2003), United Kingdom (2005), Dubai (2007), Australia/New Zealand and Canada (2008), Hong-Kong (2011), Germany, Austria, Spain, Italy, Portugal, Switzerland, Belgium, Netherlands (all opened in 2012), India (2014), Brazil (2016) and Turkey (2017).
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://bangs.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Stago"> Stago
<| 产品名称 | 货号 | 化学式 | 分子量 | CAS# |
| 2,5-Anhydro-6-azido-6-deoxy-1,3-O-isopropylidene-D-glucitol | S20031 | C9H15N3O4 | 229,23 | N/A |
| 4-Azido-4-deoxy-1,6:2,3-dianhydro-β-D-mannopyranose | S97085 | C7H9N3O2 | 167,17 | N/A |
| Methyl-3,6-anhydro-7-azido-2,7-dideoxy-4,5-O-isopropylidene-D-alloheptonate | S10191 | C11H17H3O5 | 271,27 | N/A |
| 1,4-Anhydro-3-azido-2-O-benzoyl-3-deoxy-D-xylitol | S10192 | C12H13N3O4 | 263,25 | N/A |
| 1,4-Anhydro-2-azido-3-O-benzoyl-2-deoxy-D-arabitol | S10189 | C12H13N3O4 | 263,25 | N/A |
| 2-Azido-2-deoxy-1,4;3,6-dianhydro-D-glucitol | S03293 | C6H9N3O3 | 171,15 | N/A |
| 6-Azido-6-deoxy-1,2,3,4-tetra-O-acetyl-α,β-D-galactopyranose | S05174 | C14H19N3O9 | 373,32 | N/A |
| 6-Azido-6-deoxy-1,2,3,4-tetra-O-acetyl-α,β-L-galactopyranose | S02174 | C14H19N3O9 | 373,32 | N/A |
| DIBMA free acid | D-20054 | N/A | N/A | N/A |
| DIBMA monosodium salt | D-20055 | N/A | N/A | N/A |
| Glyco-DIBMA | D-20056 | N/A | N/A | N/A |
| n-Octyl α-D-glucopyranoside (aOG) > 99% highly purified | D97011 | C14H28O6 | 292,38 | 29781-80-4 |
| Methyl 6-O-(-n-heptylcarbamoyl)-α-D-glucopyranoside (HECAMEG) | D20034 | C15H29NO7 | 335,4 | 115457-83-5 |
| n-Hexyl β-D-glucopyranoside > 99% highly purified | D99014 | C12H24O6 | 264,4 | 59080-45-4 |
| n-Heptyl β-D-glucopyranoside (HeptG) > 99% highly purified | D07033 | C13H26O6 | 278,4 | 78617-12-6 |
| n-Octyl β-D-glucopyranoside (OG) > 99% highly purified | D97001 | C14H28O6 | 292,38 | 29836-26-8 |
| n-Octyl β-D-glucopyranoside (OG-C) > 99,5% for crystallography | D97001-C | C14H28O6 | 292,38 | 29836-26-8 |
| n-Nonyl β-D-glucopyranoside (NG) > 99% highly purified | D99011 | C15H30O6 | 306,40 | 69984-73-2 |
| n-Nonyl β-D-glucopyranoside (NG-C) > 99,5% for crystallography | D99011-C | C15H30O6 | 306,40 | 69984-73-2 |
| n-Decyl β-D-glucopyranoside (DG) > 99% highly purified | D99006 | C16H32O6 | 320,43 | 58846-77-8 |
| n-Undecyl β-D-glucopyranoside (UDG) > 99% highly purified | D11023 | C17H34O6 | 334,4 | 70005-86-6 |
| n-Dodecyl β-D-glucopyranoside (DDG) > 99% highly purified | D99007 | C18H36O6 | 348,5 | 59122-55-3 |
| 4-trans-(4-trans-Propylcyclohexyl)-cyclohexyl α-maltoside > 99% (t-PCCαM) | D99019-C | C27H47O11 | 547,67 | N/A |
| n-Dodecyl α-maltoside (αDDM) > 99% highly purified | D99020 | C24H46O11 | 510,63 | 116183-64-3 |
| n-Hexyl β-maltoside (HexM) > 99% highly purified | D20018 | C18H34O11 | 426,4 | 870287-95-9 |
| n-Heptyl β-maltoside (HeptM) > 99% highly purified | D14001 | C19H36O11 | 440,48 | N/A |
| n-Octyl β-maltoside (OM) > 99% highly purified | D20020 | C20H38O11 | 454,4 | 82494-08-4 |
| n-Nonyl β-maltoside (NM) > 99% highly purified | D20015 | C21H40O11 | 468,41 | 106402-05-5 |
| n-Nonyl β-maltoside (NM-C) > 99,5% for crystallography | D20015-C | C21H40O11 | 468,41 | 106402-05-5 |
| n-Decyl β-maltoside (DM) > 99% highly purified | D99003 | C22H42O11 | 482,6 | 82494-09-5 |
| n-Decyl β-maltoside (DM-C) > 99,5% for crystallography | D99003-C | C22H42O11 | 482,6 | 82494-09-5 |
| n-Undecyl β-maltoside (UDM) > 99% highly purified | D99012 | C23H44O11 | 496,6 | 253678-67-0 |
| n-Undecyl β-maltoside (UDM-C) > 99,5% for crystallography | D99012-C | C23H44O11 | 496,6 | 253678-67-0 |
| n-Dodecyl β-maltoside (DDM-C) > 99,5% for crystallography | D97002-C | C24H46O11 | 510,63 | 69227-93-6 |
| n-Tridecyl β-maltoside (TDM) > 99% | D20016 | C25H48O11 | 524,6 | 93911-12-7 |
| n-Tridecyl β-maltoside (TDM-C) > 99,5% for crystallography | D20016-C | C25H48O11 | 524,6 | 93911-12-7 |
| n-Tetradecyl β-maltoside (TeDM-C) > 99,5% for crystallography | D20028-C | C26H50O11 | 538,6 | 18449-82-6 |
| n-Pentadecyl β-maltoside (PDM-C) > 99,5% for crystallography | D20040-C | C27H52O11 | 552,35 | N/A |
| n-Hexadecyl β-maltoside (HeDM) > 99,5% | D20029-C | C28H54O11 | 566,72 | 98064-96-1 |
| n-Dodecyl β-maltoside (DDM) > 99% highly purified | D97002 | C24H46O11 | 510,63 | 69227-93-6 |
| Isopropyl 1-thio-β-D-galactopyranoside (IPTG) | S02122 | C9H18O5 | 238,30 | 367-93-1 |
| n-Heptyl 1-thio-β-D-glucopyranoside (HTG) > 99% highly purified | D99013 | C13H26O5S | 294,4 | 85618-20-8 |
| n-Octyl 1-thio-β-D-glucopyranoside (OTG) > 99% highly purified | D20014 | C14H28O5S | 308,44 | 85618-21-9 |
| n-Nonyl 1-thio-β-D-glucopyranoside (NTG-C) > 99,5% highly purified | D14038-C | C15H30O5S | 322,4 | 98854-15-0 |
| n-Decyl 1-thio-β-D-glucopyranoside (DTG) > 99% highly purified | D20021 | C16H32O5S | 336,4 | 98854-16-1 |
| n-Dodecyl 1-thio-β-maltoside (DDTM-C) > 99,5% highly purified | D20022-C | C24H46O10S | 526,6 | 148565-58-6 |
| n-Heptyl 1-thio-β-D-glucopyranoside (HTG-C) > 99,5% highly purified | D99013-C | C13H26O5S | 294,4 | 85618-20-8 |
| n-Octyl 1-thio-β-D-glucopyranoside (OTG-C) > 99,5% highly purified | D20014-C | C14H28O5S | 308,44 | 85618-21-9 |
| MEGA-8 (N-Octanoyl-N-methylglucamin) | D98004 | C15H31NO6 | 321,4 | 85316-98-9 |
| MEGA-9 (N-Nonanoyl-N-methylglucamin) | D99005 | C16H33NO6 | 335,4 | 85261-19-4 |
| MEGA-10 (N-Decanoyl-N-methylglucamin) | D99008 | C16H33NO6 | 335,4 | 85261-19-4 |
| 1-O-(n-Octyl)-tetraethyleneglycol (C8E4) | D20038 | C16H34O5 | 306,44 | 19327-39-0 |
| 1-O-(n-Decyl)-hexaethyleneglycol (C10E6) | D20041 | C22H46O7 | 422,60 | 5168-89-8 |
| 1-O-(n-Decyl)-nonaethyleneglycol (C10E9) | D20033 | C28H58O10 | 554,75 | 26183-52-81 |
| 1-O-(n-Dodecyl)-tetraethyleneglycol (C12E4) | D20035 | C20H42O5 | 362,54 | 5274-68-0 |
| 1-O-(n-Dodecyl)-octaethyleneglycol (C12E8) | D20039 | C28H58O9 | 538,75 | 3055-98-9 |
| 1-O-(n-Dodecyl)-nonaethyleneglycol (C12E9) | D20032 | C30H62O10 | 582,81 | 3055-99-0 |
| 1-O-(n-Dodecyl)-decaethyleneglycol (C12E10) | D20031 | C32H66O11 | 626,86 | 6540-99-4 |
| 1-O-(n-Tridecyl)-octaethyleneglycol (C13E8) | D20030 | C29H60O9 | 552,78 | 9043-30-5 |
| N,N-Dimethyl-n-dodecylamine-N-oxide (LDAO) | D71111 | C14H31NO | 229,4 | 1643-20-5 |
| Sucrose monolaurate (SUMOL) | S98001 | C24H44NO12 | 524,6 | 25339-99-5 |
| Monoolein (1-O-Oleoyl-rac-glycerol) | D20036 | C21H40O4 | 356,5 | 111-03-5 |
| 3-[(3-Cholamidopropyl)-dimethylammonio]-1-propane sulfonate | D99009 | C32H58N2O7S | 614,89 | 75621-03-3 |
| 3-[(3-Cholamidopropyl)-dimethylammonio]-2-hydroxy-1-propane sulfonate | D99010 | C32H58N2O8S | 630,87 | 82473-24-3 |
| n-Nonyl-phosphocholine (C9-PC) Purity > 99% | S10197 | C14H32NO4P | 309,38 | 253678-64-7 |
| n-Decyl-phosphocholine (C10-PC) Purity > 99% | S10195 | C15H34NO4P | 323,41 | 70504-28-8 |
| n-Undecyl-phosphocholine (C11-PC) Purity > 99% | S10196 | C16H36NO4P | 337,4 | 253678-65-8 |
| n-Dodecyl-phosphocholine (C12-PC) Purity > 99% | S10190 | C17H38NO4P | 351,46 | 29557-51-5 |
| n-Tridecyl-phosphocholine (C13-PC) Purity > 99% | S10198 | C18H40NO4P | 365,49 | 85775-42-4 |
| n-Tetradecyl-phosphocholine (C14-PC) Purity > 99% | S10194 | C19H42NO4P | 379,51 | 77733-28-9 |
| n-Pentadecyl-phosphocholine (C15-PC) Purity > 99% | S10199 | C20H44NO4P | 393,54 | 146801-07-2 |
| n-Hexadecyl-phosphocholine (C16-PC) Purity > 99% | S01241 | C21H46NO4P | 407,57 | 58066-85-6 |
| α-D-Galactopyranose-phosphate di-potassium salt dihydrate | P0001 | C6H11K2O9P. 2H2O | 372,36 | 19046-60-7 |
| α-D-Glucopyranose-phosphate di-potassium salt dihydrate | P0002 | C6H11K2O9P. 2H2O | 372,36 | 5996-14-5 |
| α-D-Mannopyranose-phosphate di-potassium salt dihydrate | P0003 | C6H11K2O9P. 2H2O | 372,36 | 71888-67-0 |
| N-Acetyl-D-galactosamine (2-Acetamido-2-deoxy-D-galactose, GalNAc) | S96001 | C8H15NO6 | 221,21 | 1811-31-0 |
| N-Acetyl-D-glucosamine (2-Acetamido-2-deoxy-D-glucose, GlcNAc) | S93002 | C8H15NO6 | 221,21 | 7512-17-6 |
| 2-Acetamido-2-deoxy-β-D-glucopyranosylamin | S98003 | C8H16N2O5 | 220,21 | 18615-50-4 |
| N-Acetyl-D-mannosamine x H2O (2-Acetamido-2-deoxy-D-mannose monohydrate, D-ManAc x H2O) | S94004 | C8H17NO7 | 239,23 | 7772-94-3 |
| 1,3,4,6-tetra-O-acetyl-β-D-GlcNAc (2-Acetamido-2-deoxy-1,3,4,6-tetra-O-acetyl-β-D-glucopyranose) | S94005 | C16H23NO10 | 389.36 | 7772-79-4 |
| 3,4,6-tri-O-acetyl-β-D-GlcNAc azide (2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl azide) | S96006 | C14H20N4O8 | 372,34 | 6205-69-2 |
| 3,4,6-tri-O-acetyl-α-D-GlcNAc chlorid (2-Acetamido-2-deoxy-3,4,6-tri-O-acetyl-2-deoxy-α-D-glucopyranosyl chlorid) | S97007 | C14H20CINO8 | 366,80 | 3068-34-6 |
| 1,3,4,6-tetra-O-acetyl-α-D-glucosamine x HCl (2-Amino-2-deoxy-1,3,4,6-tetra-O-acetyl-α-D-glucopyranose HCl) | S00116 | C14H22CINO9 | 383,79 | N/A |
| Allyl 2-acetamido-2-deoxy-α-D-glucopyranoside | S96008 | C11H19NO6 | 261,28 | 54400-75-8 |
| Allyl 2-acetamido-2-deoxy-β-D-glucopyranoside | S96009 | C11H19NO6 | 261,28 | 54400-77-0 |
| Allyl α-D-galactopyranoside | S96010 | C9H16O6 | 220,22 | 48149-72-0 |
| Allyl α-D-glucopyranoside | S98011 | C9H16O6 | 220,22 | 7464-56-4 |
| Allyl β-D-glucopyranoside | S98012 | C9H16O6 | 220,22 | 34384-797 |
| Allyl α-D-mannopyranoside | S11118 | C9H16O6 | 220,22 | 41308-76-3 |
| Allyl 2,3,4-tri-O-benzyl-α-D-glucopyranoside | S98013 | C30H34O6 | 490,60 | N/A |
| 1-Amino-1-deoxy-β-D-galactose (β-D-Galactopyranosylamine) | S99102 | C6H13NO5 | 179,17 | 50444-86-5 |
| 1,6-Anhydro-β-D-galactopyranose | S93014 | C6H10O5 | 162,14 | 644-76-8 |
| 1,6:3,4-Dianhydro-2-O-tosyl-β-D-galactopyranose | S97016 | C13H14O6s | 234,25 | 6167-32-4 |
| D-Arabinose | S93017 | C5H10O5 | 150,13 | 28697-53-2 |
| Arbutin (4-Hydroxyphenyl b-D-glucopyranoside, synthetic) | S96018 | C12H16O7 | 272,25 | 497-76-7 |
| 2-Azido-2-deoxy-1,3,4,6-tetra-O-acetyl-α-D-galactopyranose | S96021 | C14H19N3O9 | 373,32 | N/A |
| 2-Azido-2-deoxy-1,3,4,6-tetra-O-acetyl-α,β-D-galactopyranose | S97022 | C14H19N3O9 | 373,32 | N/A |
| 2-Azido-2-deoxy-1,3,4,6-tetra-O-acetyl-β-D-glucopyranose | S96024 | C14H19N3O9 | 373,32 | N/A |
| 2-Azido-2-deoxy-1,2‘,3,3‘,4‘,6,6‘-hepta-O-acetyl-α,β-lactose 2-Azido-2-deoxy-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-1,3,6-tri-O-acetyl-α,β-D-glucopyranose | S96025 | C26H35N3O17 | 661,58 | N/A |
| 2-Azido-2-deoxy-1,3,4,6-tetra-O-acetyl-α-D-mannopyranose | S97026 | C14H19N3O9 | 373,32 | N/A |
| Benzyl 4,6-O-benzylidene-α-D-GlcNAc | S97027 | C22H25NO6 | 399,45 | 13343-63-0 |
| Benzyl α-D-GlcNAc (Benzyl 2-acetamido-2-deoxy-α-D-glucopyranoside) | S97028 | C15H21NO6 | 311,34 | 13343-62-9 |
| Benzyl α-D-mannopyranoside | S97029 | C13H18O6 | 270,28 | 155548-45-5 |
| Cellobiose | S96030 | C12H22O11 | 342,30 | 528-50-7 |
| 6-Deoxy-1,2:3,4-di-O-isopropylidene-α-D-galactopyranose | S96032 | C12H20O5 | 244,29 | 4026-27-1 |
| 3,4-Di-O-acetyl-L-rhamnal (3,4-Di-O-acetyl-6-deoxy-L-glucal) | S94035 | C10H14O5 | 214.22 | 34819-86-8 |
| 1,4:3,6-Dianhydro-D-mannitol | S97037 | C6H10O4 | 146,15 | 641-74-7 |
| 1,2,3,4-Di-O-isopropylidene-α-D-galactopyranose | S95038 | C12H20O6 | 260.29 | 4064-06-6 |
| 1,2:5,6-Di-O-isopropylidene-α-D-glucofuranose | S00112 | C12H20O6 | 260,29 | 582-52-5 |
| 1,2:5,6-Di-O-isopropylidene-D-mannitol | S95039 | C12H22O6 | 262,31 | 1707-77-3 |
| 2,3:5,6-Di-O-isopropylidene-α-D-mannofuranose | S93040 | C12H20O6 | 260.29 | 14131-84-1 |
| 1,2:3,5-Di-O-isopropylidene-α-D-xylofuranose | S00110 | C11H18O5 | 230,26 | 20881-04-3 |
| D-Fucose (6-Deoxy-D-galactose) | S96042 | C6H12O6 | 164,16 [3615-37-0] | 3615-37-0 |
| L-Fucose (6-Deoxy-L-galactose) | S96043 | C6H12O6 | 164,16 | 2438-80-4 |
| D-Galactosamine x HCl | S95044 | C6H13NO5 x HCl | 215.64 | 1172-03-8 |
| D-Glucosamine x HCl | S93045 | C6H13NO5 x HCl | 215.64 | 66-84-2 |
| L-Glucose | S94046 | C6H12O6 | 180.16 | 921-60-8 |
| 2,3,3’,4,6,6’-Hexa-O-acetyl-lactal | S97036 | N/A | N/A | |
| 1,2-O-Isopropylidene-α-D-glucofuranose | S00113 | C9H16O6 | 220,22 | 18549-40-1 |
| Isopropyl-β-D-thiogalactoside IPTG (lactose based) | S02122-L | C9H18O5S | 238,31 | 367-93-1 |
| Isopropyl-β-D-thiogalactoside IPTG (on plant based) | S02122-P | C9H18O5S | 238,31 | 367-93-1 |
| 3,4-O-Isopropylidene-D-mannitol | S94048 | C9H18O6 | 222,22 | 369-84-4 |
| 1,2-O-Isopropylidene-α-D-xylofuranose | S00111 | C8H14O5 | 190,20 | 20031-21-4 |
| D-Lyxose | S96051 | C5H10O5 | 150,13 | 1114-34-7 |
| L-Lyxose | S96052 | C5H10O5 | 150,13 | 1949-78-6 |
| Maltose monohydrate | S98053 | C12H22O11H2O | 360,32 | 6363-53-7 |
| β-Maltose octaacetate | S98054 | C28H38O19 | 678,63 | 22352-19-8 |
| D-Mannose | S93057 | C6H12O6 | 180.16 | 3458-28-4 |
| L-Mannose | S94058 | C6H12O6 | 180.16 | 10030-80-5 |
| Methyl 4,6-O-benzylidene-β-D-galactopyranoside | S96060 | C14H18O6 | 282,30 | 6988-39-2 |
| Methyl 4,6-O-benzylidene-α-D-glucopyranoside | S97061 | C14H18O6 | 282,30 | 3162-96-7 |
| Methyl 4,6-O-benzylidene-β-D-glucopyranoside | S98062 | C14H18O6 | 282,30 | 6988-39-2 |
| Methyl 6-deoxy-α-L-mannopyranoside (Methyl a-L-rhamnopyranoside) | S96063 | C7H14O5 | 178,19 | 15814-59-2 |
| Methyl α-D-fucopyranoside | S96064 | C7H14O5 | 178,19 | 1128-40-1 |
| Methyl α-L-fucopyranoside | S96065 | C7H14O5 | 178,19 | 14687-15-1 |
| Methyl β-D-galactopyranoside | S96066 | C7H14O6 | 194,18 | 1824-94-8 |
| Methyl β-D-glucopyranoside hemihydrate | S96067 | C7H14O6 | 194,18 | 7000-27-3 |
| Methyl β-D-ribopyranoside | S97068 | C6H12O5 | 164,16 | 17289-61-1 |
| Methyl 2,3,5-tri-O-benzoyl-α-D-arabinofuranoside | S98069 | C27H24O8 | 476,49 | N/A |
| 1,2,3,4,6-Penta-O-acetyl-β-D-galactopyranose | S95072 | C16H22O11 | 390,35 | 4163-60-4 |
| 1,2,3,4,6-Penta-O-acetyl-α-D-mannopyranose | S99070 | C16H22O11 | 390,35 | 4163-65-9 |
| D-Raffinose pentahydrate | S96074 | C18H32O16 5H2O | 594,53 | 17629-30-0 |
| L-Rhamnose monohydrate | S94075 | C6H14O6 | 182.17 | 10030-85-0 |
| D-Ribose | S93076 | C5H10O5 | 150.13 | 50-69-1 |
| L-Ribose | S93077 | C5H10O5 | 150.13 | 24259-59-4 |
| D-Tagatose | S93079 | C6H12O6 | 180.16 | 87-81-0 |
| α-D-Talose | S93080 | C6H12O6 | 180.16 | 2595-98-4 |
| 2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl azide | S96081 | C14H19N3O9 | 373,32 | 13992-26-2 |
| 2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl bromide | S96082 | C14H19BrO9 | 411.21 | 3068-32-4 |
| 2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl azide | S96083 | C14H19N3O9 | 373,32 | 13992-25-1 |
| 2,3,4,6-Tetra-O-acetyl-α-D-glucopyranosyl bromide | S94084 | C14H19BrO9 | 411.21 | 572-09-8 |
| 1,3,4,6-Tetra-O-acetyl-β-D-mannopyranose | S97086 | C14H20O10 | 348,31 | 18968-05-3 |
| 2,3,4,6-Tetra-O-acetyl-α-D-mannopyranose | S97087 | C14H20O10 | 348,31 | N/A |
| 1,2,3,5-Tetra-O-acetyl-β-D-ribofuranose | S94088 | C13H18O9 | 318.28 | 13035-61-5 |
| 2,3,4,6-Tetra-O-acetyl-1-thio-β-D-galactopyranose | S94089 | C14H20O9S | 364.37 | N/A |
| 2,3,4,6-Tetra-O-acetyl-1-thio-β-D-glucopyranose | S94090 | C14H20O9S | 364.37 | 19879-84-6 |
| 2,3,4,6-Tetra-O-benzyl-α-D-galactopyranose | S96091 | C34H3606 | 540.66 | 5308-25-7 |
| 2,3,4,6-Tetra-O-benzyl-α-D-glucopyranose | S93092 | C34H3606 | 540.66 | 4132-28-9 |
| 2,3,4,6-Tetra-O-benzyl-α-D-mannopyranose | S96093 | C34H3606 | 540.66 | 61330-61-8 |
| 1-Thio-β-D-galactose sodium salt | S96094 | C6H11NaO5S | 218,21 | 42891-22-5 |
| 1-Thio-β-D-glucose sodium salt dihydrate | S94095 | C6H11NaO5S x 2 H2O | 254.24 | 10593-29-0 |
| 3,4,6-Tri-O-acetyl-D-galactal | S94097 | C12H16O7 | 272.26 | 4098-06-0 |
| D-Turanose (α-D-Glcp(1-3)-D-fructose) | S93100 | C12H22O11 | 342.30 | 547-25-1 |
| D-Xylose | S93101 | C5H10O5 | 150.13 | 58-86-6 |
| 1,6-Anhydro-β-D-glucopyranose (Levoglucosan) | S93015 | C6H10O5 | 162,14 | 498-07-7 |
| 2-Azido-2-deoxy-1,3,4,6-tetra-O-acetyl-α-D-glucopyranose | S96023 | C14H19N3O9 | 373,32 | N/A |
我们承诺:
(1)专业的服务:为您提供包括购买咨询、技术支持及实验方案制定在内的全方位服务;
(2)迅捷的货期:利用国际化的物流平台,大大缩短产品从厂家到最终用户的时间;
(3)过硬的品质:确保正品、质量和售后,多年客户积累,口碑保证。
公司简介:
艾美捷科技有限公司经营范围涵盖分子生物学试剂、免疫学试剂、细胞生物学试剂、蛋白质研究试剂、微生物学试剂、化学及生化试剂、材料学试剂、天然提取物、仪器设备等9大门类,累计约10万余种产品,充分满足不同客户的个性化需求;公司代理国外50余种一线品牌试剂,以“高性价比、迅捷的物流速度、专业的技术支持”,让客户充分享受全球化带来的便利;公司还增加了基因编辑、蛋白表达、细胞鉴定等定制项目,大大提升了为客户服务能力。“不忘初心,方得始终”,艾美捷科技将继续秉持“专心、专业、为您”的宗旨,以客户为根本,以诚信为基础,持续地为各界客户提供更加优质的产品和服务。
Glycon Biochemicals GmbH; Glycon Biochem; Glycon; S20031; S97085; S10191; S10192; S10189; S03293; S05174; S02174; D-20054; D-20055; D-20056; D97011; D20034; D99014; D07033; D97001; D97001-C; D99011; D99011-C; D99006; D11023; D99007; D99019-C; D99020; D20018; D14001; D20020; D20015; D20015-C; D99003; D99003-C; D99012; D99012-C; D97002-C; D20016; D20016-C; D20028-C; D20040-C; D20029-C; D97002; S02122; D99013; D20014; D14038-C; D20021; D20022-C; D99013-C; D20014-C; D98004; D99005; D99008; D20038; D20041; D20033; D20035; D20039; D20032; D20031; D20030; D71111; S98001; D20036; D99009; D99010; S10197; S10195; S10196; S10190; S10198; S10194; S10199; S01241; P0001; P0002; P0003; S96001; S93002; S98003; S94004; S94005; S96006; S97007; S00116; S96008; S96009; S96010; S98011; S98012; S11118; S98013; S99102; S93014; S97016; S93017; S96018; S96021; S97022; S96024; S96025; S97026; S97027; S97028; S97029; S96030; S96032; S94035; S97037; S95038; S00112; S95039; S93040; S00110; S96042; S96043; S95044; S93045; S94046; S97036; S00113; S02122-L; S02122-P; S94048; S00111; S96051; S96052; S98053; S98054; S93057; S94058; S96060; S97061; S98062; S96063; S96064; S96065; S96066; S96067; S97068; S98069; S95072; S99070; S96074; S94075; S93076; S93077; S93079; S93080; S96081; S96082; S96083; S94084; S97086; S97087; S94088; S94089; S94090; S96091; S93092; S96093; S96094; S94095; S94097; S93100; S93101; S93015; S96023; 10030-80-5; 10030-85-0; 10593-29-0; 106402-05-5; 106402-05-5; 111-03-5; 1114-34-7; 1128-40-1; 115457-83-5; 116183-64-3; 1172-03-8; 13035-61-5; 13343-62-9; 13343-63-0; 13992-25-1; 13992-26-2; 14131-84-1; 146801-07-2; 14687-15-1; 148565-58-6; 155548-45-5; 15814-59-2; 1643-20-5; 1707-77-3; 17289-61-1; 17629-30-0; 1811-31-0; 1824-94-8; 18449-82-6; 18549-40-1; 18615-50-4; 18968-05-3; 19046-60-7; 19327-39-0; 1949-78-6; 19879-84-6; 20031-21-4; 20881-04-3; 22352-19-8; 24259-59-4; 2438-80-4; 25339-99-5; 253678-64-7; 253678-65-8; 253678-67-0; 253678-67-0; 2595-98-4; 26183-52-81; 28697-53-2; 29557-51-5; 29781-80-4; 29836-26-8; 29836-26-8; 3055-98-9; 3055-99-0; 3068-32-4; 3068-34-6; 3162-96-7; 34384-797; 3458-28-4; 34819-86-8; 3615-37-0; 367-93-1; 367-93-1; 367-93-1; 369-84-4; 4026-27-1; 4064-06-6; 4098-06-0; 41308-76-3; 4132-28-9; 4163-60-4; 4163-65-9; 48149-72-0; 497-76-7; 498-07-7; 50444-86-5; 50-69-1; 5168-89-8; 5274-68-0; 528-50-7; 5308-25-7; 54400-75-8; 54400-77-0; 547-25-1; 572-09-8; 58066-85-6; 582-52-5; 58846-77-8; 58-86-6; 59080-45-4; 59122-55-3; 5996-14-5; 61330-61-8; 6167-32-4; 6205-69-2; 6363-53-7; 641-74-7; 644-76-8; 6540-99-4; 66-84-2; 69227-93-6; 69227-93-6; 6988-39-2; 6988-39-2; 69984-73-2; 69984-73-2; 7000-27-3; 70005-86-6; 70504-28-8; 71888-67-0; 7464-56-4; 7512-17-6; 75621-03-3; 7772-79-4; 7772-94-3; 77733-28-9; 78617-12-6; 82473-24-3; 82494-08-4; 82494-09-5; 82494-09-5; 85261-19-4; 85261-19-4; 85316-98-9; 85618-20-8; 85618-20-8; 85618-21-9; 85618-21-9; 85775-42-4; 870287-95-9; 87-81-0; 9043-30-5; 921-60-8; 93911-12-7; 93911-12-7; 98064-96-1; 98854-15-0; 98854-16-1

LC Laboratories(LC Labs)公司成立于1980年,一直专注于信号转导,肿瘤以及其他临床前试剂的研究和生产,主要提供抗癌物质、酶抑制剂、激活剂和离子通道试剂。LC Labs公司不但拥有大规模的制备液相色谱纯化能力,也开发和优化了大量的具有自主知识产权的低成本高纯度生成方法,其生产的小分子试剂纯度高、价格低和销量大。
1980年,LC Labs是PMA(佛波醇12-豆蔻酸 13醋酸;TPA)的全球主要生产商,36年来的销售量超过150,000瓶;1989年为研究试剂市场提供第一个纯度高价格低的毒萝卜素;1990年提供第一个纯度高价格低的冈田酸;1991年提供第一个纯度高价格低的花萼海绵诱癌素A,并且持续是这种广泛使用的磷酸酶抑制剂的全球主要生产商;1995年提供第一个异构体级别纯度的低价格Gö 6976;1996年提供第一个纯度高价格低的罗霉素A1;2002年提供第一个纯度高价格低的雷帕霉素(抗真菌抗生素);同年,提供第一个纯度高、价格低的FK-506;2003年提供第一个纯度高价格低的来普霉素B;2004年提供第一个纯度高价格低的星孢菌素;同年,提供第一个纯度高价格低的环巴胺;2007年,LC Labs公司为临床前肿瘤相关研究引入第一组纯度高价格低的常用蛋白激酶抑制剂。
热销产品:
Bortezomib硼替佐米(99%,97%)
Cyclosporine-A环胞霉素A
Cyclopamine环巴胺
17-DMAG,Hydrochloride SaltHSP90抑制剂
Everolimus依维莫司
FK-506他克莫司
Forskolin腺苷酸环化酶激活剂
Gefitinib吉非替尼
Leptomycin B细霉素B 出核转运抑制剂
LY 294002PI3-K抑制剂
PD98059MEK抑制剂
RoscovitineCDK抑制剂
Rapamycin雷帕霉素
SB 202190MAPK抑制剂
SB203580P38MAPK抑制剂
SP600125JNK抑制剂
Staurosporine星孢菌素
UO126MAPK抑制剂
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://bangs.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="LC Laboratories"> LC Laboratories地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18327026838
传真:13212737804
邮箱:sales@amyjet.com
0.3475